Clinical trials referenced in this document:
Documents that mention this clinical trial
Updated efficacy of adjuvant epirubicin plus cyclophosphamide followed by taxanes versus carboplatin plus taxanes in early triple-negative breast cancer in phase 2 trial: 8.1-year median follow-up
Funding for this research was provided by:
national key r&d program of china (2018YFC0115204)
csco pilot oncology research fund (Y-2019AZMS-0377)
capital health development research project (2018-2-4023)
non-profit central research institute fund of chinese academy of medical sciences clinical and translational medicine research fund (12019XK320071)
Received: 22 June 2021
Accepted: 26 September 2021
First Online: 14 October 2021
: All authors declare that they have no conflict of interest.
: The study was carried out in accordance with the Declaration of Helsinki.
: Good Clinical Practice Guidelines and was also approved by the ethics committees of the participating hospitals.
: Not applicable.